ICER
ICER
  • ICER Analytics™
  • ICER Scientific Advice
  • Donate
search
  • Who We Are
    • History & Impact
    • People
    • Independent Funding
    • Careers
    • Frequently Asked Questions (FAQs)
  • Our Approach
    • Methods & Process
    • Policies
  • Engage with ICER
    • Patient Portal
    • Clinicians
    • Manufacturers
    • Prospective Employees
    • Committees & Boards
  • News & Insights
    • Press Releases
    • Commentaries
    • Journal Articles
    • Weekly View
  • Explore Our Research
    • Assessments
    • Policy Papers
    • ICER Calendar
    • ICER ANALYTICS™
Explore Our Research / Assessments / Parkinson’s Disease

Parkinson’s Disease

An assessment of tavapadon

Public Meeting
October 2026

Assessment Status

Open

Public Comments

OpenView

Closed

Upcoming Milestone

Evidence ReportView

  • Overview
  • Full Timeline & Materials
  • Related Assessments & Articles

Interventions of Interest

For questions please contact [email protected].

  • tavapadon (AbbVie Inc.)

Register here for the October 1st public meeting.

Main Review
October 1, 2026

CTAF

The CTAF 2026 public meeting on treatment for Parkinson’s Disease

ICER STAKEHOLDER OUTREACH AND PUBLIC COMMENTERS LIST

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review.

  • AbbVie Inc.
  • American Parkinson’s Disease Association
  • Amneal Pharmaceuticals
  • Davis Phinney Foundation
  • Humana
  • Michael J Fox Foundation
  • Parkinson’s Foundation
  • Parkinson’s and Movement Disorders Alliance
  • Union Chimique Belge (UCB)
  • Veterans Affairs

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

Register for Meeting
Parkinson’s Disease Meeting Agenda

Public Comment Period

See Full Timeline
07/27/2026 - 08/25/2026

Public Comments on Draft Evidence Report

Submit a Public Comment

Related Assessments & Policy Papers.

Woman_in_passing

Amyotrophic Lateral Sclerosis (ALS)

Aug 2022

Alzheimer’s Disease

Jul 2021

Alzheimer’s Disease

Mar 2023

Alzheimer’s Disease: Evaluating Diagnostics

Dec 2012
03/09/2026

Draft Scoping Document

Download PDF

03/09/2026 - 03/27/2026

Public Comments on Draft Scoping Document

Download PDF

04/07/2026

Revised Scoping Document

Download PDF

04/16/2026

Research Protocol

Please find the research protocol here: https://osf.io/thkp9/files/tc8su

06/03/2026

Model Analysis Plan

Please find the model analysis plan here: https://osf.io/thkp9/files/tx7n5

07/29/2026

Draft Evidence Report

Having trouble viewing the report? Click here. 

 

Download PDF

Draft Voting Questions

07/27/2026 - 08/25/2026

Public Comments on Draft Evidence Report

Submit a Public Comment

09/16/2026

Evidence Report

10/01/2026

Evidence Presentation

11/02/2026

Final Evidence Report and Meeting Summary

Related Assessments & Policy Papers

Alzheimer’s Disease

Mar 2023 CTAF

Amyotrophic Lateral Sclerosis (ALS)

Aug 2022 Midwest CEPAC

Alzheimer’s Disease

Jul 2021 CTAF

Alzheimer’s Disease: Evaluating Diagnostics

Dec 2012

Related Press Releases

Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Parkinson’s Disease

Public comment period now open until August 25, 2026; Requests to make oral comment during public meeting also being accepted.

Read More 07/29/2026

Institute for Clinical and Economic Review to Assess Treatment for Parkinson’s Disease

Report will be subject of CTAF meeting in October 2026; Draft Scoping Document open to public comment until March 27, 2026.

Read More 03/09/2026
Back to Top
  • Contact
  • Careers
  • Find a Report
  • Donate
  • ICER ANALYTICS™ LOGIN

OUR NEWSLETTER.

A weekly digest of the top news
on ICER and US drug pricing. Sign Up


CONTACT US

+1 (617) 528-4013

Email: [email protected]

Media Inquiries: [email protected]

ICER
© ICER, 2026
  • Terms and Conditions
  • Privacy Policy
  • Accessibility Statement
Linkedin
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT